Neuropathology of type 2 diabetes: A short review on insulin-related mechanisms

European Neuropsychopharmacology

Volumn 24, Issue 12, 2014, Pages 1961-1966

  Guerrero Berroa, Elizabeth ^a   Schmeidler, James ^a   Beeri, Michal Schnaider ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Neuropathology; Review; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E4; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; ATHEROGENESIS; BLOOD VESSEL INJURY; CEREBROVASCULAR DISEASE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; ANIMAL; BRAIN; COMPLICATION; HYPERINSULINISM; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN;

EID: 84918778025     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.01.019     Document Type: Article

References (58)

1. Ahtiluoto S. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010, 75(13):1195-1202. 10.1212/WNL.0b013e3181f4d7f8.
2. Aronson S.M. Intracranial vascular lesions in patients with diabetes mellitus. J. Neuropathol. Exp. Neurol. 1973, 32(2):183-196.
3. Arvanitakis Z. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006, 67(11):1960-1965. 10.1212/01.wnl.0000247053.45483.4e.
4. Beeri M.S. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J. Gerontol. Ser. A: Biol. Sci. Med. Sci. 2005, 60(4):471-475.
5. Beeri M.S. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008, 71(10):750-757. 10.1212/01.wnl.0000324925.95210.6d.
6. Beeri M.S. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech. Ageing Dev. 2011, 132(11-12):583-587. 10.1016/j.mad.2011.10.007.
7. Cefalu W.T. Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. ILAR J. 2006, 47(3):186-198.
8. Cholerton B., Baker L.D., Craft S. Insulin, cognition, and dementia. Eur. J. Pharmacol. 2013, 719(1-3):170-179. 10.1016/j.ejphar.2013.08.008.
9. Cole G.M., Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp. Gerontol. 2007, 42(1-2):10-21. 10.1016/j.exger.2006.08.009.
10. Combs C.K. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000, 20(2):558-567.
11. Cook D.G. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J. Pathol. 2003, 162(1):313-319.
12. Craft S. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003, 28(6):809-822.
13. de la Monte S.M. Alzheimer's disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2008, 2(6):1101-1113.
14. Delarue J., LeFoll C., Corporeau C., Lucas D. n-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?. Reprod. Nutr. Dev. 2004, 44(3):289-299.
15. Delerive P. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 2001, 169(3):453-459.
16. Dickson D.W., Sinicropi S., Yen S.-H., Ko L.-W., Mattiace L.A., Bucala R., Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol. Aging 1996, 17(5):733-743. 10.1016/0197-4580(96)00116-9.
17. Farris W. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci.-PNAS 2003, 100(7):4162-4167. 10.1073/pnas.0230450100.
18. Furth A.J. Glycated proteins in diabetes. Br. J. Biomed. Sci. 1997, 54(3):192-200.
19. Ganda O.P. Studies on streptozotocin diabetes. Diabetes 1976, 25(7):595-603.
20. Gasparini L. Does insulin dysfunction play a role in Alzheimer's disease?. Trends Pharmacol. Sci. (Regular ed.) 2002, 23(6):288-293.
21. Genuth S. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54(11):3103-3111.
22. Gold S.M. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50(4):711-719. 10.1007/s00125-007-0602-7.
23. Greig N.H. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42(1):45-50. 10.1007/s001250051111.
24. Grünblatt E. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 2007, 101(3):757-770. 10.1111/j.1471-4159.2006.04368.x.
25. Heitner J. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 1997, 49(5):1306-1311.
26. Ho L. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18(7):902-904. 10.1096/fj.03-0978fje.
27. Hong M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 1997, 272(31):19547-19553. 10.1074/jbc.272.31.19547.
28. Jakobsen J. Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes 1987, 36(5):597-601.
29. Kameyamai M., Fushmi H., Udaka F. Diabetes mellitus and cerebral vascular disease. Diabetes Res. Clin. Pract. 1994, 24(Suppl. 0):S205-S208. 10.1016/0168-8227(94)90250-X.
30. Li L. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 2007, 56(2):384-402. 10.1016/j.brainresrev.2007.09.001.
31. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Greig N.H. GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimer's Dis. 2010, 19(4):1205-1219. 10.3233/jad-2010-1314.
32. Li Y.M. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Neurosci. Lett. 1997, 226(3):155-158.
33. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Cole G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25(12):3032-3040.
34. McCance D.R. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Investig. 1993, 91(6):2470-2478. 10.1172/jci116482.
35. Monnier L. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA: J. American Med. Assoc. 2006, 295(14):1681-1687. 10.1001/jama.295.14.1681.
36. Moroz N. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J. Alzheimer's Dis. 2008, 15(1):29-44.
37. Münch G. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. neural Transm. 1998, 105(4-5):439-461.
38. Nelson P.T., Smith C.D., Abner E.A., Schmitt F.A., Scheff S.W., Davis G.J., Markesbery W.R. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2009, 1792(5):454-469. 10.1016/j.bbadis.2008.08.005.
39. Pathan A.R. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006, 79(23):2209-2216. 10.1016/j.lfs.2006.07.018.
40. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 2002, 51(4):1256-1262.
41. Pérez A. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 2000, 25(2):247-255.
42. Plaschke K. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J. Alzheimer's Dis. 2010, 19(2):691-704.
43. Puskás L.G., Kitajka K., Nyakas C., Barcelo-Coblijn G., Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc. Natl. Acad. Sci. USA 2003, 100(4):1580-1585.
44. Reger M.A. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimer's Dis. 2008, 13(3):323-331.
45. Rivera E.J. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimer's Dis. 2005, 8(3):247-268.
46. S Roriz-Filho J. (Pre)diabetes, brain aging, and cognition. Biochim. Biophys. Acta: Mol. Basis Dis. 2009, 1792(5):432-443. 10.1016/j.bbadis.2008.12.003.
47. Sasaki N. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 1998, 153(4):1149-1155. 10.1016/s0002-9440(10)65659-3.
48. Southern L. Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol. 2007, 7(1):35. 10.1186/1471-2377-7-35.
49. Stranahan A.M. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 2008, 11(3):309-317. 10.1038/nn2055.
50. Talbot K. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Investig. 2012, 122(4):1316-1338. 10.1172/jci59903.
51. Umegaki H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration?. Age Ageing 2010, 39(1):8-10. 10.1093/ageing/afp211.
52. US Census Bureau, 2012. 2012 National Population Projections: Table 3. Percent distribution of the projected population by selected age groups and sex for the United States: 2015 to 2060 (NP2012-T3), Available from:. http://www.census.gov/population/projections/data/national/2012/summarytables.html.
53. van Deutekom A.W. Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus. Eur. J. Endocrinol. 2008, 158(5):655-660. 10.1530/eje-08-0024.
54. van Harten B. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006, 29(11):2539-2548. 10.2337/dc06-1637.
55. van Harten B. Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing 2007, 36(2):164-170. 10.1093/ageing/afl180.
56. Wang Z. Prevention of high- and low-dose STZ-induced diabetes with D-glucose and 5-thio-D-glucose. Diabetes 1993, 42(3):420-428.
57. Wild S. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
58. Wrighten S.A., Piroli G.G., Grillo C.A., Reagan L.P. A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2009, 1792(5):444-453. 10.1016/j.bbadis.2008.10.013.